Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1–5 years
- 1 September 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 59 (5-6), 411-415
- https://doi.org/10.1007/s00228-003-0639-6
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Oral oseltamivir treatment of influenza in childrenThe Pediatric Infectious Disease Journal, 2001
- Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in ChildrenPediatric Drugs, 2001
- Development of a high-performance liquid chromatographic–mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- The Impact of Influenza Epidemics on HospitalizationsThe Journal of Infectious Diseases, 2000
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000
- Drug trials in children: problems and the way forwardBritish Journal of Clinical Pharmacology, 2000
- Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young ChildrenNew England Journal of Medicine, 2000
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in ChildrenNew England Journal of Medicine, 2000
- Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802Clinical Pharmacokinetics, 1999
- Developmental patterns of renal functional maturation compared in the human neonateThe Journal of Pediatrics, 1978